NCT01989884View on ClinicalTrials.gov

An Efficacy Study Of Ortataxel In Recurrent Glioblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2016

Conditions
Glioblastoma
Interventions
DRUG

Ortataxel

75 mg/m2, IV (in the vein) every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.

Trial Locations (7)

20133

Carlo Besta Neurological Foundation, Milan

Unknown

Ospedale di Lecco, Lecco

A.O. OSpedale Niguarda Ca' Granda, Milan

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan

"Fondazione Salvatore Maugeri", Pavia

"IRCCS Fondazione Casimiro Mondino", Pavia

Istituti Fisioterapici Ospitalieri, Rome

All Listed Sponsors
lead

Mario Negri Institute for Pharmacological Research

OTHER

NCT01989884 - An Efficacy Study Of Ortataxel In Recurrent Glioblastoma | Biotech Hunter | Biotech Hunter